MetiMedi Pharmaceuticals is a clinical-stage pharmaceutical company investigating new methods of modulating cell metabolism to develop innovative therapy for cancers and chronic inflammatory diseases.
At MetiMedi, expertise in R&D of cell metabolism modulators is applied to develop novel therapeutics designed to improve patients’ lives and satisfy high unmet medical needs. OMT-110, a promising small molecule cancer cell metabolism modulator, strongly inhibits tumor growth in animal models without considerable side effects. OMT-110 has completed scheduled dosing in phase I clinical trials as of early 2019 and is currently under planning for phase II clinical trials for various cancers.
MetiMedi Pharmaceuticals is also investigating cell metabolism modulators in chronic inflammatory diseases including non-alcoholic fatty liver disease (NASH), inflammatory bowel disease (IBD), Rheumatoid arthritis (RA), age-related macular degeneration (AMD), cardiovascular disease, periodontal disease, atherosclerosis, Alzheimer and Parkinson’s disease. Treatment with OMT-210 prompted remodeling of the inflammatory environment and yielded significant improvement of disease status in animal models.
MetiMedi Pharmaceuticals has a strong commitment to satiate high unmet medical needs through full development of our innovative assets such as OMT-110 and MEMI-101. We are actively pursuing license agreements to proceed our studies from the preclinical stages to market launch. Our goal is to progress the clinical development of our discoveries, substantially increase their values, and to ultimately market or out-license.